Preclinical trial of dual BRD4/PI3K inhibitor SF2523 [257] as well as a few of clinical trials of PI3K/AKT inhibitors may develop new therapeutic strategies for PCa patients (Tables 2 and 3). The gene discussed is AKT1; the disease is posterior cortical atrophy.